RDHL: Rasio kapitalisasi marang pendapatan RedHill Biopharma Ltd

Logo korporat perusahaan RedHill Biopharma (RDHL)

RedHill Biopharma relies on unique FDA-approved formulas, which create a defensive barrier in patent disputes. The historical P/S ratio illustrates the price-to-sales dynamics, where the 0.30 mark indicates the current valuation level. Regional conflicts in Israel may disrupt logistics, but the global status of the drugs and US patents minimize the overall pressure on the business.

RDHL: Multiplikator P/S RedHill 04.07.2022 - 30.09.2024

Rincian metrik lan analitis perusahaan RedHill Biopharma Ltd. (RDHL)

- kuotasi saiki lan rata-rata prakiraan nilai:
Ringkesan analitik perusahaan:RedHill, RDHL
Sampel barang redhillbio.com

The monopoly status of RedHill Biopharma (RDHL) in the treatment of gastrointestinal infections allows the company to maintain strict pricing power, which directly impacts revenue dynamics. By analyzing this revenue valuation metric, an investor determines the cost per unit of sales; a sharp increase in the multiple signals market optimism, however, an excessive gap between market capitalization and actual earnings increases the risk of a deep correction should sales growth slow.